Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: Dawn of a new era

Leukemia Research

Volumn 28, Issue 5, 2004, Pages 429-442

  Nabhan, Chadi ^a   Gartenhaus, Ronald B ^b   Tallman, Martin S ^b  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

2 Chlorodeoxyadenosine; Chronic lymphocytic leukemia; Fludarabine; Monoclonal antibodies; Nucleoside analogues; Pentostatin

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; FLUCONAZOLE; FLUDARABINE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; MITOXANTRONE; MONOCLONAL ANTIBODY; PENTOSTATIN; PETHIDINE; PREDNISONE; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB; UNINDEXED DRUG;

ANEMIA; B CELL LEUKEMIA; BACTERIAL INFECTION; CEREBELLUM INFARCTION; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; FEVER; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEADACHE; HEMATOLOGIC MALIGNANCY; HERPES; HUMAN; HYPOTENSION; INFECTION; LEUKEMIA REMISSION; LEUKOPENIA; LISTERIOSIS; MORTALITY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTICEMIA; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; HUMANS; LEUKEMIA, B-CELL, CHRONIC; PENTOSTATIN; VIDARABINE;

EID: 1842455198     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.08.017     Document Type: Review

References (121)

1. Greenlee R.T., Hill-Harmon M.B., Murray T.et al. Cancer statistics 2001. CA Cancer J. Clin. 51:2001;15-36.
2. Rai K.R., Sawitsky A., Cronkite E.P.et al. Clinical staging of chronic lymphocytic leukemia. Blood. 46:1975;219-234.
3. Rai K.R., Peterson B.L., Appelbaum F.R.et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343:2000;1750-1757.
4. Weiss M.A. A phase I and II study of pentostatin (Nipent) with cyclophosphamide for previously treated patients with chronic lymphocytic leukemia. Semin. Oncol. 27:2000;41-43.
5. Keating M.J., O'Brien S., Lerner S.et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 92:1998;1165-1171.
6. O'Brien S.M., Kantarjian H.M., Cortes J.et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J. Clin. Oncol. 19:2001;1414-1420.
7. Plunkett W., Huang P., Gandhi V. Metabolism and action of fludarabine phosphate. Semin. Oncol. 17:1990;3-17.
8. Cass C. Nucleoside Transport. In: Georgopapakakou N, editor. Drug Transport in Antimicrobial and Anticancer Chemotherapy. New York: Marcel Dekker, 1994.
9. Crawford C.R., Ng C.Y., Noel L.D.et al. Nucleoside transport in L1210 murine leukemia cells. Evidence for three transporters. J. Biol. Chem. 265:1990;9732-9736.
10. Molina-Arcas M., Bellosillo B., Casado F.J.et al. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood. 101:2003;2328-2334.
11. W Plunkett VG. Cellular metabolism of nucleoside analogues in CLL. In: Cheson B, editor. implications for drug development in chronic lymphocytic leukemia: scientific advances and clinical developments. New York: Marcel Dekker, 1993.
12. Gandhi V., Kemena A., Keating M.J.et al. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk. Lymphoma. 10:1993;49-56.
13. Albertioni F., Lindemalm S., Reichelova V.et al. Pharmacokinetics of cladribine in plasma and its 5′-monophosphate and 5′-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin. Cancer Res. 4:1998;653-658.
14. Huang P., Sandoval A., Van Den Neste E.et al. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia. 14:2000;1405-1413.
15. Dohner H., Fischer K., Bentz M.et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 85:1995;1580-1589.
16. Gartenhaus R.B., Wang P., Hoffman M.et al. The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine. J. Mol. Med. 74:1996;143-147.
17. Montogomery J., Hewson K. Nucleosides of 2-fluoroadenine. J. Med. Chem. 12:1969;498-504.
18. Malspeis L., Grever M.R., Staubus A.E.et al. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Semin. Oncol. 17:1990;18-32.
19. Noker P.E., Duncan G.F., El Dareer S.M.et al. Disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-phosphate in mice and dogs. Cancer Treat Rep. 67:1983;445-456.
20. Sirotnak F.M., Chello P.L., Dorick D.M.et al. Specificity of systems mediating transport of adenosine, 9-beta-D-arabinofuranosyl-2-fluoroadenine, and other purine nucleoside analogues in L1210 cells. Cancer Res. 43:1983;104-109.
21. Plunkett W., Chubb S., Alexander L.et al. Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D- arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res. 40:1980;2349-2355.
22. Avramis V.I., Plunkett W. Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388. Cancer Res. 42:1982;2587-2591.
23. Boogaerts M.A., Van Hoof A., Catovsky D.et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 19:2001;4252-4258.
24. Keating M.J., Kantarjian H., Talpaz M.et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 74:1989;19-25.
25. Montserrat E., Lopez-Lorenzo J.L., Manso F.et al. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. Leuk. Lymphoma. 21:1996;467-472.
26. Sorensen J.M., Vena D.A., Fallavollita A.et al. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. J. Clin. Oncol. 15:1997;458-465.
27. Hiddemann W., Unterhalt M., Pott C.et al. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-grade non-Hodgkin's lymphoma Study Group. Semin. Oncol. 20:1993;28-31.
28. Bergmann L., Fenchel K., Jahn B.et al. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann. Oncol. 4:1993;371-375.
29. Johnson S., Smith A.G., Loffler H.et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 347:1996;1432-1438.
30. Leporrier M., Chevret S., Cazin B.et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 98:2001;2319-2325.
31. Keating M.J., Smith T.L., Lerner S.et al. Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk. Lymphoma. 37:2000;71-85.
32. O'Brien S., Kantarjian H., Beran M.et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 82:1993;1695-1700.
33. Girmenia C., Mauro F.R., Rahimi S. Late listeriosis after fludarabine plus prednisone treatment. Br. J. Haematol. 87:1994;407-408.
34. Zinzani P.L., Bendandi M., Magagnoli M.et al. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Ann. Oncol. 8:1997;379-383.
35. Caracciolo F., Capochiani E., Papineschi F.et al. A new effective treatment for indolent lymphoma: a pilot study with fludarabine, idarubicin and prednisone combination (FLIDA). Hematol. Oncol. 15:1997;27-31.
36. Bellosillo B., Villamor N., Colomer D.et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood. 94:1999;2836-2843.
37. Morabito F., Callea I., Console G.et al. The in vitro cytotoxic effect of mitoxantrone in combination with fludarabine or pentostatin in B-cell chronic lymphocytic leukemia. Haematologica. 82:1997;560-565.
38. Weiss M., Spiess T., Berman E.et al. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia. 8:1994;1290-1293.
39. Elias L., Stock-Novack D., Head D.R.et al. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study. Leukemia. 7:1993;361-365.
40. Gandhi V., Robertson L.E., Keating M.J.et al. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother. Pharmacol. 34:1994;30-36.
41. Robertson L.E., O'Brien S., Kantarjian H.et al. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia. 9:1995;943-945.
42. Tosi P., Zinzani P.L., Pellacani A.et al. Loxoribine affects fludarabine activity on freshly isolated B-chronic lymphocytic leukemia cells. Leuk. Lymphoma. 26:1997;343-348.
43. Tosi P., Pellacani A., Zinzani P.L.et al. In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells. Haematologica. 84:1999;794-798.
44. Marotta G., Bigazzi C., Lenoci M.et al. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica. 85:2000;1268-1270.
45. Mauro F.R., Foa R., Meloni G.et al. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Haematologica. 87:2002;926-933.
46. Flinn I., Byrd J., Morrison C.et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 96:2000;71-75.
47. Hallek M., Schmitt B., Wilhelm M.et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br. J. Haematol. 114:2001;342-348.
48. Cazin B., Binet J., Divine M.et al. Oral fludarabine and cyclophosphamide in previously untreated chronic lymphocytic leukemia: preliminary data. Blood. 96:2000;515a.
49. Seto S., Carrera C.J., Kubota M.et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J. Clin. Invest. 75:1985;377-383.
50. Hentosh P., McCastlain J.C., Blakley R.L. Effects of 2-chloro-2′- deoxyadenosine 5′-triphosphate on DNA synthesis in vitro by purified bacterial and viral DNA polymerases. Biochemistry. 30:1991;547-554.
51. Carson D.A., Wasson D.B., Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc. Natl. Acad. Sci. U.S.A. 81:1984;2232-2236.
52. Kearns C.M., Blakley R.L., Santana V.M.et al. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res. 54:1994;1235-1239.
53. Juliusson G., Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol. 11:1993;679-689.
54. Juliusson G., Liliemark J. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann. Oncol. 7:1996;373-379.
55. Tallman M.S., Hakimian D., Zanzig C.et al. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 13:1995;983-988.
56. Saven A., Piro L.D. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia and chronic lymphocytic leukemia. Leuk. Lymphoma. 11(Suppl 2):1993;109-114.
57. O'Brien S., Kantarjian H., Estey E.et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N. Engl. J. Med. 330:1994;319-322.
58. Byrd J.C., Peterson B., Piro L.et al. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia. 17:2003;323-327.
59. Alessi-Severini S., Gati W.P., Belch A.R.et al. Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. Leukemia. 9:1995;1674-1679.
60. Juliusson G., Christiansen I., Hansen M.M.et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J. Clin. Oncol. 14:1996;2160-2166.
61. Saven A., Lemon R.H., Kosty M.et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J. Clin. Oncol. 13:1995;570-574.
62. Robak T., Blonski J.Z., Urbanska-Rys H.et al. 2-Chlorodeoxyadenosine (cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia. 13:1999;518-523.
63. Robak T., Blasinska-Morawiec M., Blonski J.Z.et al. 2- Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. Leuk. Lymphoma. 34:1999;151-157.
64. Begleiter A., Verburg L., Ashique A.et al. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-beta-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia. 9:1995;1875-1881.
65. Morabito F., Stelitano C., Callea I. 2-Chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features. Haematologica. 81:1996;224-231.
66. Tefferi A., Levitt R., Li C.Y.et al. Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemia. Am. J. Clin. Oncol. 22:1999;509-516.
67. Robak T., Blonski J.Z., Kasznicki M.et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood. 96:2000;2723-2739.
68. Robak T., Blonski J.Z., Kasznicki M.et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients. Br. J. Haematol. 108:2000;357-368.
69. Tefferi A., Li C.Y., Reeder C.B.et al. A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia. Leukemia. 15:2001;1171-1175.
70. Fox R.M., Tripp E.H., Taylor I.W. Deoxyadenosine induced G1 phase arrest in leukemic T cells. Adv. Exp. Med. Biol. 165(Pt B):1984;333-338.
71. Carson D.A., Wasson D.B., Kaye J.et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc. Natl. Acad. Sci. U.S.A. 77:1980;6865-6869.
72. Major P.P., Agarwal R.P., Kufe D.W. Clinical pharmacology of deoxycoformycin. Blood. 58:1981;91-96.
73. Venner P.M., Glazer R.I., Blatt J.et al. Levels of 2′- deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia. Cancer Res. 41:1981;4508-4511.
74. Major P.P., Agarwal R.P., Kufe D.W. Deoxycoformycin: neurological toxicity. Cancer Chemother. Pharmacol. 5:1981;193-196.
75. Ho A.D., Thaler J., Stryckmans P.et al. Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer. J. Natl. Cancer Inst. 82:1990;1416-1420.
76. Dillman R.O., Mick R., McIntyre O.R. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B. J. Clin. Oncol. 7:1989;433-438.
77. Grever M.R., Leiby J.M., Kraut E.H.et al. Low-dose deoxycoformycin in lymphoid malignancy. J. Clin. Oncol. 3:1985;1196-1201.
78. Dohner H., Ho A.D., Thaler J.et al. Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. J. Natl. Cancer Inst. 85:1993;658-662.
79. Weiss M.A., Maslak P.G., Jurcic J.G.et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 21:2003;1278-1284.
80. Waselenko J.K., Grever M.R., Beer M.et al. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia. Semin. Oncol. 27:2000;44-51.
81. Nadler L.M., Stashenko P., Hardy R.et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 40:1980;3147-3154.
82. Dillman R.O. Monoclonal antibodies for treating cancer. Ann. Intern. Med. 111:1989;592-603.
83. Davis T.A., Grillo-Lopez A.J., White C.A.et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18:2000;3135-3143.
84. Reff M.E., Carner K., Chambers K.S.et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20m. Blood. 83:1994;435-445.
85. McLaughlin P., Grillo-Lopez A.J., Link B.K.et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16:1998;2825-2833.
86. Nguyen D.T., Amess J.A., Doughty H.et al. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur. J. Haematol. 62:1999;76-82.
87. Petryk M., Grossbard M.L. Rituximab therapy of B-cell neoplasms. Clin. Lymphoma. 1:2000;186-194. discussion 195-6.
88. Manshouri T., Do K.A., Wang X.et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 101:2003;2507-2513.
89. Schulz H., Klein S.K., Rehwald U.et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 100:2002;3115-3120.
90. Byrd J.C., Peterson B.L., Morrison V.A.et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 101:2003;6-14.
91. Yamauchi T., Nowak B.J., Keating M.J.et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin. Cancer Res. 7:2001;3580-3589.
92. Manero G.G., O'Brien S., Cortes J.et al. Update of results of the combination of fludarabine, cyclophosphamide, and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). Blood. 98:2001;633a.
93. Wierda W., O'Brien S., Albitar M.et al. Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood. 98:2001;771a.
94. Drapkin R. Pentostatin and rituximab in the treatment of patients with B-cell malignancies. Oncology (Huntingt). 14:2000;25-29.
95. Rai K., Gupta N., Janson D.et al. Rituximab/cyclophosphamide/ dexamethasone combination highly effective in autoimmune hemolytic anemia associated with chronic lymphocytic leukemia. Blood. 96:2000;754a.
96. Gupta N., Patel D., Kavuru S.et al. Re-treatment with a rituximab based therapy is highly effective in autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia (CLL). Blood. 98:2001;363a.
97. Golay J., Xiao Y., Gaetano N.et al. Fludarabine synergises with anti-CD20 monoclonal antibody Rituximab in complement mediated cell lysis. Blood. 96:2000;339a.
98. Johnson T.A., Press O.W. Synergistic cytotoxicity of iodine-131-anti- CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas. Int. J. Cancer. 85:2000;104-112.
99. Di Gaetano N., Xiao Y., Erba E.et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. J. Haematol. 114:2001;800-809.
100. Keating M.J., Flinn I., Jain V.et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 99:2002;3554-3561.
101. Osterborg A., Dyer M.J., Bunjes D.et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J. Clin. Oncol. 15:1997;1567-1574.
102. Rai K.R., Freter C.E., Mercier R.J.et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J. Clin. Oncol. 20:2002;3891-3897.
103. Kennedy B., Rawstron A., Evans P.et al. Campath-1H therapy in 29 patients with refractory CLL: true complete remission is an attainable goal. Blood. 94:1999;603a.
104. Rai K., Coutre S., Rizzieri D.et al. Efficacy and safety of Almetuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis. Blood. 98:2001;365a.
105. Kennedy B., Rawstron A., Carter C.et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 99:2002;2245-2257.
106. Elter T., Brochmann P., Jensen M.et al. Development of a new, four-weekly schedule (Flucam) with concomitantapplication of Campath-1H and fludarabine in patients with relapsed/refractory CLL. Blood. 100:2002;803a.
107. Thai C., Nguyen D., Dugan K.et al. Incidence of cytomegalovirus (CMV) viremia during Campath-1H therapy for relapsed/refractory chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL). Blood. 98:2001;366a.
108. Nabhan C., Rosen S.T. Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia. Semin. Oncol. 29:2002;75-80.
109. Nabhan C., Tallman M., Riley M.et al. Phase I study of Rituximab and Campath-1H in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 98:2001;365a.
110. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101(9):3413-3415.
111. Byrd J.C., Murphy T., Howard R.S.et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19:2001;2153-2164.
112. Anaissie E., Kontoyiannis D.P., Kantarjian H.et al. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann. Intern. Med. 117:1992;466-469.
113. Juliusson G. Complications in the treatment of CLL with purine analogues. Hematol. Cell Ther. 39(Suppl 1):1997;S41-S44.
114. Schmitt B., Kneba M., Ritgen M.et al. First line therapy of patients with advanced chronic lymphocytic leukemia (CLL) older than 65 years with fludarabine versus chlorambucil: interim analysis of a phase III study of the German CLL Study Group (GCLLSG). Blood. 100:2002;387a.
115. Keating M.J., O'Brien S., Kantarjian H.et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 81:1993;2878-2884.
116. Robak T., Blonski J.Z., Kasznicki M.et al. Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leukemia. 15:2001;1510-1516.
117. Robak T., Gora-Tybor J., Lech-Maranda E.et al. Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. Eur. J. Haematol. 66:2001;188-194.
118. Huhn D., von Schilling C., Wilhelm M.et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 98:2001;1326-1331.
119. O'Brien S.M., Kantarjian H., Thomas D.A.et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 19:2001;2165-2170.
120. Hainsworth J.D., Litchy S., Burris H.A. 3rdet al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J. Clin. Oncol. 20:2002;4261-4267.
121. Thomas D., O'Brien S., Giles F.et al. Single agent rituxan in early stage chronic lymphocytic leukemia (CLL). Blood. 98:2001;364a.